comprehensive -WSS

comprehensive

author：knowledge 2025-09-06 03:33:25 - browse：4982

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： BD to buy Edwards patient monitoring unit for $4.2 billion

hotspot

WSS

One Duchenne patient's bittersweet hope for new treatment

STAT wants to know your pick for a great summer read or listen

Eli Lilly’s Zepbound improved liver scarring in mid

ASCO Daily Recap: CAR

Superbugs, antibiotic resistance get scrutiny in congress

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Jerome Adams on the need for new antivirals for Covid

Antibody drugs appear effective. Now can we make enough of them?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Elevance PBM president out as customers face prescription chaos

How to save PrEP access — and even expand it

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

As demand for Covid shots wanes, Moderna seeks its next success

Is there an 'orca uprising'? Like orcas themselves, the answer is complex.

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Inflation cooled significantly in June, bringing price hikes close to normal levels

focus

FTC loses bid to block Novant's North Carolina hospital merger

EU fines Illumina $475 million over Grail acquisition

Giant panda gives birth to squirming, squealing healthy twin girls at South Korean theme park

FDA approves Moderna’s RSV vaccine, its second licensed product

Watch the official trailer for 'Ahsoka' series

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

hotspot

hotspot

focus

focus